Background Acute myeloid leukemia (AML) is associated with poor prognosis, particularly in
elderly patients with comorbidities. Combining azacitidine (AZA) with BCL-2 inhibitor …

The variable dosage forms of most traditional Chinese medicines (TCMs) could be
disadvantaged by low selectivity, poor biological distribution, limited bioavailability with low …

Chemotherapeutic nucleoside analogs, such as cytarabine (Ara-C), are incorporated into
genomic DNA during replication. Incorporated Ara-CMP (Ara-cytidine monophosphate) …

Daunorubicin (Dnr) is at the forefront of acute myeloid leukemia (AML) therapy, but drug
resistance poses a major threat to treatment success. MicroRNA (miR)-9 has been shown to …

Abstract Purpose of Review With the recent approval of multiple new drugs for the treatment
of acute myeloid leukemia (AML), the relevance of conventional treatment approaches, such …

Acute myeloid leukemia (AML) is a highly heterogeneous hematological neoplasm with low
survival rates. Thus, the investigation of new therapeutic targets is essential. The Rac …

Introduction This study aims to evaluate the efficacy and safety of the novel combination of
Aza and HIA as the frontline induction therapy in newly diagnosed AML patients eligible for …

The immune system has a variety of potential effects on a tumor microenvironment and the
course of chemotherapy may vary according to that. Anticancer treatments can encourage …

Background Acute myeloid leukemia (AML) presents ongoing therapeutic challenges due to
its intricate molecular pathogenesis. This study aimed to elucidate the role of RNA binding …

Background Patients with acute myeloid leukaemia frequently have thrombocytopenia
during induction chemotherapy. Eltrombopag, an oral thrombopoietin receptor agonist …